Thank you, and thanks for joining. I'm very happy today to present our top line 24-month eGFR results from our study of sibeprenlimab in IgA nephropathy. Next slide, please. As you're aware, IgA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results